清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA.

医学 奥西默替尼 表皮生长因子受体 肿瘤科 化疗 内科学 癌症研究 受体 埃罗替尼
作者
Jamie E. Chaft,Walter Weder,Jianxing He,Ke‐Neng Chen,Maximilian J. Hochmair,Jin‐Yuan Shih,Sung Yong Lee,Kang-Yun Lee,Nguyễn Thị Hồng Nhung,Somcharoen Saeteng,Carlos Henrique Andrade Teixeira,Carles Escriu,Alex Martínez‐Martí,Collin M. Blakely,Yasushi Yatabe,Sanja Dacic,Xiangning Huang,Yuri Rukazenkov,Anupriya Dayal,Masahiro Tsuboi
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 8001-8001 被引量:3
标识
DOI:10.1200/jco.2025.43.16_suppl.8001
摘要

8001 Background: Based on the Ph 3 ADAURA study, adjuvant (adj) treatment (Tx) with osi, a 3rd-generation, EGFR-TKI, is SoC for resected EGFRm stage (stg) IB–IIIA NSCLC (AJCC 7th ed). Neoadj Tx may improve surgical and long-term outcomes. NeoADAURA (NCT04351555) is a global, Ph 3, randomized, controlled, 3-arm study assessing outcomes with neoadj osi ± CT vs CT alone, in EGFRm R-NSCLC. Methods: Eligible pts: aged ≥18 yrs; WHO PS ≤1; EGFRm (Ex19del/L858R) stg II–IIIB (AJCC 8th ed) R-NSCLC. Pts were stratified (stg II vs III; non-Asian vs Chinese vs other Asian; Ex19del vs L858R) and randomized 1:1:1 to neoadj osi 80 mg QD (≥9 wks) + CT (cis/carboplatin + pemetrexed; 3 cycles, Q3W), osi monotherapy (mono) 80 mg QD (≥9 wks) or placebo (PBO) QD + CT (3 cycles, Q3W). Osi/PBO + CT: double blind; osi mono: open label, sponsor blind. Adj osi was offered to all pts who completed surgery (Sx). Primary endpoint: major pathological response (MPR) by blinded central pathology review. Secondary endpoints included pathological complete response (pCR), event-free survival (EFS), and safety. Data cut-off: Oct 15, 2024. Results: Overall, 358 pts were randomized: osi + CT n=121/osi mono n=117/PBO + CT n=120; baseline characteristics were generally balanced across the respective arms (stg II: 49%/50%/51%; non-Asian: 27%/26%/25%; Ex19del: 50%/51%/51%). After neoadj Tx, 92%/97%/89% of pts underwent Sx in the osi + CT/osi mono/PBO + CT arms. Osi + CT (MPR rate 26%) and osi mono (25%) showed statistically significant improvement in MPR vs PBO + CT (2%): odds ratios were 19.8 (p<0.0001) and 19.3 (p<0.0001), respectively. Interim EFS (15% maturity) trended in favor of osi + CT and osi mono vs PBO + CT (Table); ≥80% of pts in each arm received adj osi. In the neoadj period, grade ≥3 all-cause AEs and AEs leading to discontinuation of any Tx occurred in 36%/13%/33% and 9%/3%/5% of pts, respectively, for osi + CT/osi mono/PBO + CT. No pts died within 30 days of Sx. Conclusions: Neoadj osi with or without CT showed statistically significant improvement in the MPR rate over CT alone. EFS data were immature and trended in favor of the osi containing arms. There were no new safety concerns. Neoadj osi ± CT should be considered when planning Tx for pts with EGFRm stg II–IIIB R-NSCLC. Clinical trial information: NCT04351555 . Osi + CT (n=121) Osi mono(n=117) PBO + CT(n=120) MPR rate, % (95% CI)Difference vs PBO + CT, % (95% CI)Odds ratio vs PBO + CT (adjusted 100×[1−alpha]% CI)p-value 26 (18, 34)24 (15, 32)19.8 (4.6, 85.3 a ) <0.0001 25 (17, 34)23 (15, 32)19.3 (1.7, 217.4 b ) <0.0001 2 (<1, 6)––– pCR rate, % (95% CI) 4 (1, 9) 9 (4, 15) 0 (0, 3) 12-mo EFS rate, % (95% CI)EFS hazard ratio vs PBO + CT (CI)p-valueMedian EFS follow-up, mos (range) f 93 (87, 97)0.50 (0.17, 1.41 c ) 0.0382 e 16 (0–42) 95 (89, 98)0.73 (0.40, 1.35 d ) –18 (2–42) 83 (75, 89)––19 (2–42) a 95.002% CI; b 99.9% CI; c 99.8% CI; d 95% CI; e p-value ≤0.002 required for statistical significance at interim analysis; f censored pts.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慧子完成签到 ,获得积分10
9秒前
yuer完成签到 ,获得积分10
28秒前
xue完成签到 ,获得积分10
50秒前
Unshouable发布了新的文献求助10
52秒前
Unshouable完成签到,获得积分10
1分钟前
cadcae完成签到,获得积分10
1分钟前
孤独剑完成签到 ,获得积分10
2分钟前
汉堡包应助科研通管家采纳,获得10
2分钟前
Kao应助科研通管家采纳,获得10
2分钟前
Kao应助科研通管家采纳,获得10
2分钟前
Kao应助科研通管家采纳,获得10
2分钟前
吉吉国王完成签到 ,获得积分10
2分钟前
睡不醒完成签到 ,获得积分10
2分钟前
zy完成签到 ,获得积分10
2分钟前
3分钟前
希望天下0贩的0应助12123采纳,获得10
3分钟前
西山菩提完成签到,获得积分10
3分钟前
滕祥发布了新的文献求助200
3分钟前
4分钟前
Nene完成签到 ,获得积分10
4分钟前
Kao应助科研通管家采纳,获得10
4分钟前
Kao应助科研通管家采纳,获得10
4分钟前
斯文败类应助科研通管家采纳,获得10
4分钟前
不想起床完成签到 ,获得积分10
4分钟前
4分钟前
woxinyouyou完成签到,获得积分0
4分钟前
不甜的唐发布了新的文献求助10
5分钟前
紫熊发布了新的文献求助10
5分钟前
5分钟前
脑洞疼应助CY-a301E采纳,获得10
5分钟前
不甜的唐完成签到,获得积分10
5分钟前
在水一方应助qayqay003采纳,获得30
5分钟前
蛋黄啵啵完成签到 ,获得积分10
5分钟前
知野纪完成签到 ,获得积分10
5分钟前
5分钟前
5分钟前
5分钟前
CY-a301E发布了新的文献求助10
5分钟前
5分钟前
CY-a301E完成签到,获得积分10
6分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
《上海印钞厂志》 3000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场现状调查及投资机会研判报告 1000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
模型平均及其应用 900
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
作者名:Kristopher P. Plain,悉尼大学的,目前只能查到其四篇论文,想找到其博士论文 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7338937
求助须知:如何正确求助?哪些是违规求助? 8952326
关于积分的说明 18998711
捐赠科研通 6991238
什么是DOI,文献DOI怎么找? 3218421
关于科研通互助平台的介绍 2384180
邀请新用户注册赠送积分活动 2198382